# Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct05838066/  
OnCo record `nct05838066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HB1801 in HER2-positive breast cancer, now recruiting.

## Summary

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT05838066, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. Planned enrolment is 880 participants (estimated). The study started in 2023-07-23 and primary completion is expected in 2025-07-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05838066
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
- Sponsor: Shanghai JMT-Bio
- Enrolled: 880

## Sources

- ClinicalTrials.gov NCT05838066: https://clinicaltrials.gov/study/NCT05838066

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [HB1801](https://onco.cc/drugs/hb1801/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct05838066.json